Third, the key tasks:
1, commonly used medical isotopes (such as Mo99, I 125, I 13 1, C 14, etc. ) and medical isotopes with broad application prospects (Ra223, 68Ge/68Ga, Re 186/65438). Relying on the advantages of China National Nuclear Corporation and two nuclear reactors, China Tongfu is expected to obtain the exclusive distribution right of related isotopes after the Group breaks through relevant technologies.
2. Research and development of radiopharmaceuticals. When China Tongfu 20 18 went on the market, many radioactive nuclear drugs were brewing to keep pace with the international market, but the progress has been slow. After the release of this medium-and long-term development plan, we can expect the progress of relevant R&D pipelines.
3. Develop high-end diagnostic equipment SPECT/CT and PET/CT. CNNC High Energy, owned by Tongfu, has a forward-looking layout in this respect.
4. The R&D capability of the accelerator is improved. Tongfu and IONETIX of the United States set up a joint venture company in China, preparing to localize the Ionetix cyclotron. Under the principle of "at least one domestic medical isotope production accelerator should be established in prefecture-level cities", it is expected to seize market share quickly.
5. Improve the capacity of existing reactors and build new medical isotope production reactors. CNNC can undertake related tasks.
6. Establish a national platform for research and development and industrial transformation of radiopharmaceuticals, coordinate and promote the research and development, clinical transformation and application of radiopharmaceuticals, and optimize the existing diagnosis and treatment programs. As a subsidiary of central enterprises, China Tongfu is duty-bound to participate in the construction of relevant platforms, and its core executives all hold important positions in the academic fields related to nuclear medicine, which is expected to benefit from the platform construction.
7. Implement the promotion plan of nuclear medicine, and promote the full coverage of "one county, one department" and nuclear medicine departments of tertiary general hospitals. Compared with the existing 1 148 nuclear medicine department (data of 20 19), it is necessary to build at least twice as many new departments, and at the same time, F 18 is expected to be included in medical insurance according to procedures.
8, deepen international cooperation and exchanges, and gradually realize the "going out" of medical isotopes in China. China Tongfu is undoubtedly in the forefront of the industry in terms of international exports.
Fourth, safeguard measures.
1. Optimize industrial policies and encourage social capital to enter the field of medical isotopes.
2. Strengthen personnel training, bring up a group of leading talents in disciplines, introduce a group of high-tech talents in a targeted manner, and solve the talent constraint problem of industry development.
The copyright belongs to the author. Please contact the author for authorization for commercial reprinting, and please indicate the source for non-commercial reprinting.
Risk warning: The opinions expressed in this article only represent personal opinions, and it is not recommended to involve the subject matter. So trading on this basis is at your own risk.